Company Overview

Lipocine Inc. is a U.S.-based biopharmaceutical company focused on the development of oral drug delivery solutions for therapeutics that traditionally require non-oral administration. The company operates primarily within the biotechnology and pharmaceutical development industries, with a strategic emphasis on endocrine disorders and metabolic diseases. Lipocine’s core competency lies in its proprietary Lip’ral® drug delivery technology, which is designed to enable the effective oral delivery of poorly bioavailable drugs.

Lipocine’s primary revenue drivers are licensing agreements and development-related milestone payments rather than large-scale commercial sales. The company targets patient populations requiring hormone replacement or metabolic therapies, particularly in the men’s health and endocrinology markets. Founded in 1997 and headquartered in Utah, Lipocine has evolved from an early-stage formulation company into a clinical-stage biopharmaceutical firm with an FDA-approved product licensed to a commercial partner.

Business Operations

Lipocine operates as a single reporting segment focused on pharmaceutical research and development. Its business activities center on advancing a pipeline of oral drug candidates leveraging its Lip’ral® technology, which improves absorption of lipophilic drugs through the lymphatic system. The company does not currently maintain its own commercial sales infrastructure and instead relies on partners for commercialization.

Key product candidates include TLANDO®, an oral testosterone replacement therapy approved by the U.S. Food and Drug Administration, as well as investigational candidates such as LPCN 1144 for non-alcoholic steatohepatitis and LPCN 1148 for postpartum depression. Lipocine’s operations are primarily domestic, with clinical trials and regulatory interactions conducted in the United States, and limited international clinical activities through contracted research organizations.

Strategic Position & Investments

Lipocine’s strategy centers on advancing differentiated oral formulations of established therapeutics and monetizing them through licensing and collaboration agreements. A major strategic achievement was the licensing of TLANDO® to Antares Pharma, which later became part of Halozyme Therapeutics following its acquisition. This partnership provides Lipocine with milestone and royalty-based revenue tied to commercialization outcomes.

The company continues to invest in late-stage clinical development for select pipeline assets while maintaining a capital-efficient operating model. Lipocine has not pursued a broad acquisition strategy; instead, it focuses on internal development and selective partnerships that validate its technology platform. Its emerging areas of focus include metabolic disease and central nervous system-related indications where oral delivery may offer competitive advantages.

Geographic Footprint

Lipocine is headquartered in Salt Lake City, Utah, and its operations are primarily concentrated in the United States. The company conducts most of its research, development, and regulatory activities domestically, supported by U.S.-based clinical trial sites and vendors.

Internationally, Lipocine has limited direct operational presence but engages globally through clinical research organizations and regulatory consultants as needed for development programs. Its commercial reach outside the United States is indirect and dependent on partners’ strategies and market expansion efforts.

Leadership & Governance

Lipocine is led by an experienced management team with backgrounds in pharmaceutical development, regulatory strategy, and corporate finance. The leadership emphasizes disciplined capital allocation, platform validation through partnerships, and a focus on addressing unmet medical needs with patient-friendly oral therapies.

• Mahesh Patel – President & Chief Executive Officer
• Mahesh Patel – Co-Founder
• David J. Clark – Chief Financial Officer
• Scott McNab – Chief Operating Officer
• Bradley J. Younggren – Chief Medical Officer

The company is governed by a board of directors that provides oversight on strategic direction, risk management, and shareholder interests, consistent with U.S. public company governance standards.